Clinical studies, like SURMOUNT trials, show that tirzepatide has greater anti-obesity effects than semaglutide, promoting weight and fat mass reduction, appetite suppression, energy expenditure, insulin sensitivity, and glycemic parameters in obese [120] and diabetic patients [121]. This evidence concerns the gene INS and obesity disorder.